Alexandria Posts $20.44B Market Cap, 35.8M SF Assets and Ranks 2nd Among NYC Life Science Investors
ARE•Alexandria Real Estate Equities held a $20.44 billion market cap and 35.8 million square feet as of March 31, 2026, while its venture arm ranked second in New York City early-stage life science investing. Its Megacampus model opened Manhattan’s first life science campus and supported multibillion-dollar exits like a $14.6 billion Intra-Cellular Therapies sale.
1. Portfolio Scale and Market Position
Alexandria Real Estate Equities held a $20.44 billion market cap and 35.8 million square feet of operating properties as of March 31, 2026, placing it among the largest owners of life science real estate in North America.
2. Venture Investment Success
Through Alexandria Venture Investments, the company ranked second in New York City early-stage life science investing and achieved notable exits, including Petra Pharmaceuticals’ sale to Eli Lilly and a $14.6 billion Intra-Cellular Therapies acquisition by Johnson & Johnson.
3. Megacampus Model and Cluster Development
The company’s Megacampus™ model delivered Manhattan’s first life science campus, catalyzing collaboration and innovation despite regulatory and policy headwinds, and underpins its strategy to foster sustainable growth within key innovation clusters.
